Cancer treatment is growing more complex as personalized therapies and immunotherapies reshape patient care. Each patient's journey is becoming increasingly unique, demanding greater precision from oncologists and care teams alike. #CancerCare #Oncology

VERAXA Biotech (NASDAQ: VRXA) is advancing its oncology pipeline and securing industry partnerships after its June 2026 Nasdaq debut. Parent Xlife Sciences reports H1 portfolio progress across diagnostics, AI, and pharma, backed by 416 patents. #Oncology #Biotech

TransCode Therapeutics (NASDAQ: RNAZ) reports updated Phase 1a data for TTX-MC138: 71.4% of patients achieved stable disease, zero dose-limiting toxicities across 98 doses, and 40% showed longer progression-free intervals than prior therapy. #Oncology #ClinicalTrials

Helix BioPharma appoints four senior leaders to its Board, including a new Chair, as part of a major governance overhaul designed to accelerate its oncology pipeline and long-term growth strategy. #Biotech #Oncology

Telomir Pharmaceuticals (NASDAQ: TELO) raises ~$5.6M in PIPE financing to fund its FDA-cleared Phase 1/2 trial of Telomir-Zn in triple-negative breast cancer. Major shareholder John Paul DeJoria contributed $1M to the raise. #Biotech #Oncology

Kairos Pharma reports Phase 2 interim data showing ENV-105 plus apalutamide achieved 17.7 months median PFS vs. 2 months for apalutamide alone in metastatic castration-resistant prostate cancer (P=0.0008). Trial completion targeted by Q4 2027. #ProstateCancer #Oncology

NHS England now identifies brain tumor genetics in ~2 hours — down from 8 weeks. Developed at the University of Nottingham, this intraoperative tool could transform how quickly patients access targeted cancer treatments. #BrainCancer #Oncology

Lantern Pharma (NASDAQ: LTRN) announces a $4M registered direct offering at $1.09/share, with warrants that could unlock an additional $4M. Proceeds will fuel its AI-driven oncology pipeline. #Biotech #Oncology

VERAXA Biotech (NASDAQ: VRXA) advances its VXA-222 bispecific ADC into preclinical studies after completing discovery-phase collaboration with OmniAb. The 'AND-gate' design targets two tumor antigens simultaneously, aiming for greater cancer-cell selectivity. #Biotech #Oncology

BIOT (Nasdaq: BIOT) has been named authorized representative for IN01, a clinical-stage cancer immunotherapy vaccine, in Japan and China. With 2.5M annual lung cancer diagnoses globally, the stakes are high as BIOT seeks strategic partners in two key markets. #Oncology #Biotech

Onco-Innovations (ONCO) advances ONC010 cancer candidate with 99.3% purity API scale-up, CAD$5M institutional financing, and new CFO appointment as it targets a Phase 1 trial in Australia. #Oncology #Biotech

Lantern Pharma (NASDAQ: LTRN) closes a $4M registered direct offering at $1.09/share, with warrants that could yield an additional $4M. Proceeds fuel its AI-driven precision oncology pipeline. #Biopharma #Oncology